AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01515540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 5% lidoderm patch
Study NCT01515540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05272215 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
Study NCT05272215 — intervention group
Intervention type: PROCEDURE
Intervention: Body contouring surgery
Description: Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
Study NCT04643457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Study NCT02761122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy
Study NCT04506918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR survey
Description: Participants will receive an IVR survey
Study NCT04506918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS survey
Description: Participants will receive a SMS survey
Study NCT03660787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroguard
Description: Seroguard 0.41 g/L solution
Study NCT03660787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00402883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 week 1, 4, 16, 19 and 22.
Study NCT00402883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
Study NCT00402883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
Study NCT00402883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin B12
Description: 1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
Study NCT00402883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5 administered intravenously weeks 1 and 4.
Study NCT01190384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Couscous plus fiber
Description: Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
Study NCT01190384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: 300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
Study NCT01190384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean Soup
Description: Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
Study NCT02973126 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FFRct and SPECT
Description: enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
Study NCT00514072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: given intradermally
Study NCT00514072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prostate cancer vaccine ONY-P1
Description: given intradermally
Study NCT00514072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given intradermally
Study NCT03093090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 6 oz
Study NCT04493619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets
Study NCT04493619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV injection, 5 mg•min/mL
Study NCT01455090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT03093090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parmalat™ Whole Milk
Description: 6 oz
Study NCT03093090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac Pro-Advance™
Description: 6 oz
Study NCT03093090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus™
Description: 6 oz
Study NCT03093090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
Study NCT04643457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
Study NCT02694003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNBD-NDD Intervention
Description: The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
Study NCT02543450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular and task-oriented training
Study NCT02543450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb strength training program
Study NCT00963703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg Intravenously day 1 and day 15
Study NCT00972543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Efalizumab (Raptiva)
Description: Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
Study NCT00972543 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
Study NCT01066156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Study NCT02453230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lights on
Description: Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
Study NCT03890120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: 100 mg tablet administered orally once daily
Study NCT03475394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gel
Description: 0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
Study NCT03475394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morus alba gel
Description: 0.1 ml of Morus alba gel was administered into the periodontal pocket
Study NCT04643457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
Study NCT03475394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 ml of Placebo gel was administered into the periodontal pocket
Study NCT03005535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitaminized corn oil
Description: Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
Study NCT03005535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
Study NCT00597558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg white protein
Description: Egg white protein powder
Study NCT03616769 — intervention group
Intervention type: DRUG
Intervention: antiplatelet drugs ,statins ,antihypertensive drugs
Description: According to the international guidelines, we treated patients who suffered from different disease.
Study NCT02729454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice and physical therapy
Study NCT02729454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Study NCT01627756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ventilation
Description: In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
Study NCT01627756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-ventilated Group
Description: . In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Study NCT03591705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE-HAIC
Description: transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
Study NCT03591705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
Study NCT04303390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: second generation cephalosporin
Study NCT04303390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: First generation cephalosporin
Study NCT04303390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours
Description: Duration of antibiotic therapy
Study NCT04303390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 48 hours
Description: Duration of antibiotic therapy
Study NCT04002453 — intervention group
Intervention type: PROCEDURE
Intervention: Outpatient Parenteral Antibiotic Therapy
Description: Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
Study NCT04340830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
Study NCT04340830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
Study NCT01894516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.
Study NCT01894516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules.
Study NCT02975869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Leukemia Care
Study NCT02975869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Study NCT04297657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
Study NCT01117051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01117051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 or 2 mg prucalopride once daily before breakfast
Study NCT01415193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Tibial Nerve block
Description: Use of selective pain block.
Study NCT01415193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic Nerve Block
Description: Use of Sciatic Nerve Block
Study NCT01087866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01087866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT02808572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma osteoprotegerin level
Description: dosage of plasma osteoprotegerin
Study NCT02808572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 level
Description: dosage of plasma fibroblast growth factor 23
Study NCT01544595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.
Study NCT01544595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.
Study NCT01544595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02808572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular calcification score
Description: measurement of vascular calcification score by multidetection computerized tomography
Study NCT00611039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir 900mg + ritonavir 100 mg once a day
Description: Darunavir 900mg + ritonavir 100 mg once a day
Study NCT00611039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir 600mg + ritonavir 100mg twice day
Description: Darunavir 600mg + ritonavir 100mg twice day
Study NCT01464983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
Study NCT03890120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily
Study NCT04496167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase clostridium histolyticum
Study NCT01455090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT04052555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT04052555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04052555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04052555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04052555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT04496167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02839135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated scopolamine patch
Description: Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
Study NCT02839135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed scopolamine patch
Description: Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
Study NCT00156338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid management
Description: volume and sodium restriction
Study NCT00156338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluid management
Description: volume restriction
Study NCT00156338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluid management
Description: liberal fluid management
Study NCT01464983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
Study NCT01464983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
Study NCT01464983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Study NCT01464983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
Study NCT04643171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity elliptical training
Description: 30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
Study NCT04643171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrocaupuncture
Description: 30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
Study NCT05673564 — intervention group
Intervention type: PROCEDURE
Intervention: Anatomical Resection
Description: Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
Study NCT03115580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational atherectomy
Description: Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect.
Study NCT03115580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting Balloon Angioplasty
Description: Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
Study NCT03155360 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study NCT02069418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FLT-TEP
Description: Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.